Visiopro

VisioPro is a clinical-stage biotechnology company focused on developing innovative pharmacological treatments for ophthalmic conditions, with a primary emphasis on presbyopia. The company's lead candidate, VP-101, is a proprietary topical eye drop formulation designed to improve near vision by combining a muscarinic agonist and an alpha-adrenergic agonist. Founded by industry veterans Dr. David Guyer and Dr. Anthony Adamis, VisioPro was established to provide non-surgical alternatives to reading glasses for the millions of individuals affected by age-related vision loss. In July 2023, the company was acquired by Bausch + Lomb to bolster its eye care portfolio and expand its presence in the rapidly growing presbyopia market.